

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

<https://marketpublishers.com/r/M9C0B557FF6EN.html>

Date: January 2015

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: M9C0B557FF6EN

Abstracts

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need. While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia. Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years.

GILD has announced the dividend payment and now all eyes will be on CELG and BIIB

Contents

1. ACORDA THERAPEUTICS – NEUROLOGICAL PIPELINE GETTING BIGGER

Key Pipeline Drugs

- a. CVT -301 (PhIII, OFF episodes of Parkinson's disease)
- b. Dalfampridine (PhIII, post-stroke walking deficits)
- c. rHlgM22 (Remyelinating mAb, PhI)
- d. Glial Growth Factor 2 (neuregulin, PhI, GGF2)

Other Programs in the Pipeline – Future Uncertain

2. ALEXION PHARMA – PIPELINE MATURITY WILL WITNESS A STRONG 2015 FOR ALXN

Asfotase alfa (hypophosphatasia, HPP, R) on Track

Soliris in PNH and aHUS: Growth to Continue

SOLIRIS BEYOND PNH AND aHUS

Beyond Soliris

Other PhII Programs

Messenger RNA Therapeutics platform from Moderna

3. AMGEN – FOCUS ON NEW BIOLOGICS FOR LARGER MARKET AND EXPLOITING BIOLOGICS' MANUFACTURING EXPERIENCE FOR BIOSIMILARS GAIN

Newly Marketed Product: Future Growth

- a. Kyprolis
- b. BLINCYTO

Key Pipeline Products and Development

- a. Evolocumab (R, PCSK9 Inhibitor, CVD, SC)
- b. Ivabradine (R, Chronic Heart Failure):
- c. Talimogene laherparepvec
- d. Brodalumab (PhIII, moderate-to-severe plaque psoriasis and psoriatic arthritis, PhII, Asthma)
- e. Omecamtiv mecarbil (PhIIb, Heartfailure, licensed from Cytokinetics)
- f. Romosozumab (PhIII, co-developed with UCB, Postmenopausal Osteoporosis, PMO)
- g. AMG 334 (PhIIb, CGRP receptor mAb)
- h. Trebananib (PhIII, Ovarian Cancer):

i. AMG 416 (PhIII, secondary hyperparathyroidism in pt with CKD, velcalcetide)
Failed in Clinical studies
Biosimilars in Development
AMGN's Commercial Strategy

4. BIOGEN IDEC – GROWTH FROM NEWLY LAUNCHED PRODUCTS + CLINICAL MILESTONES OF NOVEL PIPELINE

Near-Term Key Pipeline Candidates to Watch
Hemophilia Franchise Offers Long-Term Opportunity
Anti-CD20 franchise Continues to Grow through Label Expansion of GAZYVA
NEUROLOGY: LEADERSHIP IN MS AND PORTFOLIO EXPANSION

5. CELGENE – INNOVATIVE STRATEGIES FOR LONG TERM GAINS

Development In Multiple Myeloma Franchise: Strengthening Pipeline
Other Oncology Drugs
Inflammation – Pipeline to start contributing to sales by 2015
Other Products in Early stage for Long Term Growth

6. GILEAD SCIENCES – POISED TO EMERGE AS A LEADER IN HCV TREATMENT

Sovaldi has made the way, Harvoni to take Lead
Pipeline: Anti-viral Franchise — HCV
Antiviral Franchise — HIV
Cardiovascular Program
Beyond Anti-Virals- Oncology
Acquisitions In Last Two Years

7. REGENERON – LATE-STAGE PIPELINE POTENTIAL – ACCELERATOR FOR FURTHER GROWTH

Label expansion of Eylea in DME, BRVO, and Myopic CNV indication
Late-Stage Pipeline
REGN-Sanofi Collaboration

8. VERTEX PHARMA – FROM LARGE VOLUME MARKET TO NICHE INDICATIONS – TRANSFORMATION HAS PAID

Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation

Small But Meaningful Addition in Other Mutations for KALYDECO monotherapy

CF BACKGROUND

Beyond CF Not a Priority

I would like to order

Product name: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

Product link: <https://marketpublishers.com/r/M9C0B557FF6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9C0B557FF6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970